within Pharmacolibrary.Drugs.R_RespiratorySystem.R06A_AntihistaminesForSystemicUse.R06AX15_Mebhydrolin;

model Mebhydrolin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.4,
    Cl = 2.1666666666666665e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Mebhydrolin</td></tr><tr><td>ATC code:</td><td>R06AX15</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>130</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Mebhydrolin is a first-generation antihistamine with anticholinergic properties, formerly used in the treatment of allergic conditions such as rhinitis, urticaria, and pruritus. It is not widely used or approved in current clinical practice in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult population as no original pharmacokinetic publications were identified.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R06AX15 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Mebhydrolin;
